Development of Innovative Drugs Lab

The Laboratory for the Development of Innovative Drugs conductsvalidation testing of approaches developed by Sharpless that aim to significantly improve the quality of drugs that affect biological and metabolic processes in the cell. New methods are based on the use of innovative click-chemistry, which is researched on different cell models, including carcinogenesis, inflammation and Alzheimer's and Parkinson's diseases. There is one doctor of sciences and six candidates of sciences among the staff working in the laboratory.

Field of research 
One of the main areas of research is the development of competitive domestic pharmaceutical products with detailed structural and functional characterization of their biological effects on various aspects of cell activity. The laboratory conducts quantitative and qualitative assessment of drugs based on multiparametric analysis of digital images of living cells. The laboratory performs research on the selection of safe and active drugs at the earliest stages of pharmaceutical preformulation development. 

One of the tasks of the laboratory is the use of the High Content Screening and Analysis platform for the validation of new targets of various diseases, including diseases of the central nervous system, cancer, inflammation, metabolic disorders and viral diseases such as hepatitis, AIDS and respiratory infections. The laboratory aims to create and apply new high-technology methods that enable the carrying out of full-fledged specification of collection of hits in terms of toxicology (cardio and hepatotoxicity) and effects (at the subcellular and cellular levels).

Sergey Leonov

Director of the Laboratory for the Development of Innovative Drugs

Roman Chupron-Netochin

Research scientist of the Laboratory for the Development of Innovative Pharmaceutical Drugs, PhD

Professional experience
Chuprov-Netochin is an expert in the development of innovative pharmaceutical drugs with the use of high-efficiency phenotypic screening platform on the latest device ImageXpress Micro XL (manufactured by Molecular Devices, USA). In the period from 2006 to 2009, he was a postgraduate student at the Institute of Bioorganic Chemistry named after M.M. Shemyakin and Y.A. Ovchinnikov of the Russian Academy of Sciences in the Laboratory of Molecular Bioengineering. His thesis work was devoted to the development of the technology for production of recombinant fibrillar proteins of T4 bacteriophage. He deeply studied a structural biology, particularly the tail fibrils folding mechanisms, he was also engaged in the crystallization of the chimeric phage proteins.
Academic Interests

Elena Marusich

The Buck Institute for Research on Aging

Caenorhabditis Genetics Center (CGC)

University of Amsterdam

Heinrich-Heine-University Düsseldorf

The Komi Biology Institute of the Scientific Center of the Ural Department of the Russian Academy of Sciences

Institute of Cell Biophysics of the Russian Academy of Sciences

ChemRar High-Tech Center

M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

S.N. Vinogradsky Institute of Microbiology of the Russian Academy of Sciences

Federal State Institution of Science State Research Center for Applied Microbiology and Biotechnology

Federal State Scientific-Industrial Company MICROGEN of the Ministry of Healthcare of the Russian Federation

  • 5 Pervomayskaya Street, Dolgoprudny, the Building of Applied Mathematics of MIPT, room 204-8 141700